Ozempic (semaglutide) lowers blood sugar in type 2 diabetes by mimicking a natural gut hormone that triggers insulin release when you eat. In real-world use, patients on a 1 mg weekly dose see an average HbA1c reduction of 1.2%, with those who stay on the medication consistently averaging a 1.4% drop. Beyond blood sugar control, the FDA has also approved Ozempic to reduce the risk of heart attacks, strokes, and cardiovascular death in people with type 2 diabetes and established heart disease, as well as to slow kidney disease progression.
How Ozempic Works in Your Body
Your intestines naturally produce a hormone called GLP-1 every time you eat. This hormone tells your pancreas to release insulin, signals your brain that you’re full, and slows digestion so nutrients enter your bloodstream more gradually. The problem is that natural GLP-1 breaks down within minutes, destroyed by an enzyme in your blood.
Ozempic is a lab-engineered version of GLP-1 designed to last much longer, which is why a single weekly injection works. Once in your system, it does three things simultaneously. First, it boosts insulin secretion, but only when your blood sugar is elevated. This glucose-dependent action is important because it means the drug carries a lower risk of causing dangerously low blood sugar compared to some older diabetes medications. Second, it suppresses glucagon, a hormone that tells your liver to dump stored sugar into your bloodstream. Third, it slows how quickly food leaves your stomach, which prevents the sharp blood sugar spikes that typically follow meals.
For long-acting versions of these drugs like Ozempic, the insulin and glucagon effects are considered the primary drivers of blood sugar control, while the slower digestion plays more of a supporting role.
Blood Sugar and HbA1c Improvements
HbA1c measures your average blood sugar over the past two to three months. For most people with type 2 diabetes, the goal is to get below 7%. In real-world data tracking patients on the 1 mg weekly dose, the average HbA1c dropped by 1.2 percentage points. Patients who stayed on the medication without gaps did even better, averaging a 1.4-point reduction. To put that in perspective, if your HbA1c starts at 8.5%, a 1.4-point drop brings you to 7.1%, right near the target range.
These reductions translate directly into lower risk of long-term diabetes complications, including nerve damage, vision loss, and kidney problems. The medication is always meant to work alongside diet and exercise, not replace them.
Weight Loss Effects
Weight loss is one of the most discussed effects of Ozempic, and it happens through a combination of reduced appetite and slower stomach emptying. The drug activates satiety centers in the brain’s hypothalamus, making you feel full sooner and less interested in food between meals. Studies on GLP-1 medications have shown participants losing an average of 10% to 15% of their body weight over a year, with the most effective drugs in this class producing losses exceeding 20%.
For someone with type 2 diabetes, this weight loss isn’t just cosmetic. Excess body fat, particularly around the midsection, drives insulin resistance. Losing even a moderate amount of weight can make your body’s own insulin work more effectively, compounding the direct blood sugar benefits of the medication itself.
Heart and Kidney Protection
In the SUSTAIN 6 trial, which followed patients with type 2 diabetes for two years, those taking semaglutide had a 26% lower rate of major cardiovascular events (heart attack, stroke, or cardiovascular death) compared to placebo. Specifically, 6.6% of patients on semaglutide experienced one of these events versus 8.9% on placebo. When data from multiple trials were combined, the overall risk reduction held at 24%.
The FDA also approved Ozempic in 2025 to reduce the risk of kidney disease progression in people with type 2 diabetes and chronic kidney disease. The FLOW trial evaluated whether semaglutide could slow declines in kidney function, delay the need for dialysis, and reduce kidney-related and cardiovascular death. This kidney indication makes Ozempic one of the few diabetes drugs with proven benefits across blood sugar, heart, and kidney outcomes.
How the Dosing Schedule Works
Ozempic is injected once a week under the skin of your abdomen, thigh, or upper arm. The dose ramps up gradually to reduce side effects. You start at 0.25 mg weekly for four weeks. This starting dose isn’t strong enough to meaningfully control blood sugar; it’s purely to let your body adjust. After four weeks, you move to 0.5 mg. If your blood sugar still needs more help after at least another four weeks, your dose can increase to 1 mg weekly. A 2 mg dose is also now available for patients who need additional control beyond 1 mg.
You can take the injection on any day of the week, as long as you keep it consistent. If you need to shift your injection day, you can do so as long as there are at least two days between doses.
Common Side Effects
The most frequent side effects are gastrointestinal: nausea, vomiting, diarrhea, abdominal pain, and constipation, each occurring in 5% or more of patients. These symptoms are most common during the dose escalation phase and tend to fade as your body adjusts. In clinical trials, gastrointestinal side effects occurred in about 31% of patients on the 1 mg dose and 34% on the 2 mg dose.
Most people tolerate the medication well enough to continue. Only about 3% to 4% of patients on the 0.5 mg or 1 mg doses discontinued treatment because of gastrointestinal problems, compared to less than 1% on placebo. Eating smaller meals and avoiding high-fat or greasy foods during the early weeks can help manage nausea.
One effect worth knowing about: the slowed stomach emptying that helps control blood sugar can, in some cases, be more pronounced than expected. In one study of patients undergoing upper endoscopy, 24% of those on semaglutide had significant residual food in their stomachs compared to just 5% of people not taking the drug. Rarely, this can lead to severe gastroparesis (stomach paralysis), which the FDA has flagged as a potential concern.
Who Should Not Take Ozempic
Ozempic carries a boxed warning about thyroid tumors. In animal studies, semaglutide caused a type of thyroid cancer called medullary thyroid carcinoma. It’s not confirmed whether this risk applies to humans, but the drug is contraindicated if you or a close family member has a history of medullary thyroid carcinoma, or if you have a condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It’s also contraindicated if you’ve had a serious allergic reaction to semaglutide in the past.
Ozempic is approved specifically for type 2 diabetes. It is not indicated for type 1 diabetes, where the pancreas produces little or no insulin, since boosting glucose-dependent insulin secretion won’t help if the cells that make insulin are destroyed.